2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD; dioxin) is a toxic environmental contaminant that works through dioxin response elements (DRE) to activate gene expression. We tested the hypothesis that cancerrelated epigenetic changes suppress dioxin activation of the cytochrome P4501A1 (CYP1A1) gene. 5-Aza-2′-deoxycytidine (5-aza-CdR), an inhibitor of DNA methylation, increases TCDD-inducible CYP1A1 mRNA expression in cancerous LNCaP cells but not in noncancerous PWR-1E and RWPE-1 cells (all human prostate cell lines). Bisulfite DNA sequencing shows that the TCDD-responsive CYP1A1 enhancer is highly methylated in LNCaP cells but not in RWPE-1 cells. In vivo footprinting experiments reveal that unmethylated DRE sites do not bind protein in response to TCDD in LNCaP cells, whereas inducible DRE occupancy occurs in RWPE-1 cells. Pretreatment of LNCaP cells with 5-aza-CdR partially restores TCDD-inducible DRE occupancy, showing that DNA methylation indirectly suppresses DRE occupancy. Chromatin immunoprecipitation experiments reveal that LNCaP cells lack trimethyl histone H3 lysine 4, a mark of active genes, on the CYP1A1 regulatory region, whereas this histone modification is prevalent in PWR-1E and RWPE-1 cells. We also analyzed CYP1A1 enhancer methylation in human prostate tissue DNA. We do not detect CYP1A1 enhancer methylation in 30 DNA samples isolated from noncancerous prostate tissue. In contrast, 11 of 30 prostate tumor DNA samples have detectable CYP1A1 enhancer methylation, indicating that it is hypermethylated in prostate tumors. This is the first report that shows that CYP1A1 is aberrantly hypermethylated in human prostate cancer and has an altered, inaccessible chromatin structure that suppresses its dioxin responsiveness. (Cancer Res 2006; 66(15) 
Introduction
DNA methylation, the covalent addition of a methyl group to the 5-carbon of cytosine in a CpG dinucleotide, is an epigenetic event that suppresses gene expression. In the human genome, CpG sites are often clustered in structures termed CpG islands that are located in the regulatory region of 12-7-18 Epigenetic Inactivation of the Dioxin-Responsive Cytochrome P4501A1 Gene in Human Prostate C… 2/16 cancerres.aacrjournals.org/content/66/15/7420.full many genes. In normal cells, most CpG islands are unmethylated and associated with active genes or genes capable of active transcription. In cancerous cells, CpG islands often become hypermethylated, leading to aberrant gene silencing ( 1-3).
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD; also called dioxin) is a notorious environmental contaminant that produces toxic, neoplastic, and reproductive effects in experimental animals ( 4, 5) and poses an unclear risk to human health ( 6) . The most well-studied dioxin response is the transcriptional induction of the cytochrome P4501A1 (CYP1A1) gene. TCDD induces CYP1A1 by binding to and activating the aryl hydrocarbon receptor (AhR), which then translocates to the nucleus and interacts with its partner protein Arnt to form an active heteromeric transcription factor (termed AhRC for AhR complex). AhRC interacts with DNA-binding sites, termed dioxin response elements (DRE), located on the CYP1A1 enhancer to mediate TCDD-inducible gene expression ( 7) .
All DRE sites contain a CpG dinucleotide ( 8) , which, when methylated in vitro, inhibits AhRC binding in an electrophoretic mobility shift assay and suppresses TCDD-inducible reporter gene activity ( 9, 10) . These findings suggest that methylation of the CYP1A1 enhancer may suppress its TCDD responsiveness.
A study analyzing lung tissue shows that CYP1A1 is methylated in humans ( 11) . CYP1A1 methylation is also observed in human and rabbit cells grown in culture ( 10, 12) . Here, we study the influence of DNA methylation and chromatin structure on dioxin action and CYP1A1 expression in cancerous and noncancerous human prostate cell lines and tissue samples. We find that the CYP1A1 enhancer is aberrantly hypermethylated in prostate cancer and has an altered, inaccessible chromatin structure that suppresses its dioxin responsiveness.
Materials and Methods
Cells and cell culture. PWR-1E, RWPE-1, and LNCaP cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured as directed. For the in vivo footprint and RNA analysis experiments, cells were split on day 0 and treated with 5-aza-2′-deoxycytidine (5-aza-CdR; Sigma, St. Louis, MO) starting on day 1 at a dose of 0.25 or 1.0 μmol/L. Culture medium was changed on day 4, and fresh 5-aza-CdR was added. Cells were treated with TCDD (10 nmol/L; Wellington Laboratories, Inc., Guelph, Ontario, Canada) on day 6 for 18 hours or on day 7 for 2 hours. Total RNA and genomic DNA were isolated on day 7 using the RNeasy Mini kit or the DNeasy Tissue kit (Qiagen, Valencia, CA), respectively, following the manufacturer's directions. To analyze CYP1A1 methylation, LNCaP cells were split on day 0 and treated with 1.0 μmol/L 5-aza-CdR starting on day 1. Culture medium was changed on day 4, and fresh 5-aza-CdR was added. Cells were split on day 7, and fresh 5-aza-CdR was added. Culture medium was changed on day 11, and fresh 5-aza-CdR was added. Genomic DNA was isolated on day 14 using the DNeasy Tissue kit.
Human prostate tissue samples. Thirty cancerous and 30 noncancerous human prostate samples were collected by radical prostatectomy and transurethral resection of the prostate, respectively, at the Shimane University School of Medicine (Shimane, Japan). Genomic DNA was isolated from the prostate samples using the QIAamp Tissue kit (Qiagen) following the manufacturer's directions.
Quantitation of mRNAs. Reverse transcription-PCR (RT-PCR) was
done using the Titanium One-Step RT-PCR kit (BD Biosciences, San (forward) and 5′-TTTGGAAATTTTGTAATAGGAAGGT-3′ (reverse); CYP1A1-14, 5′-GAGGTGAGGGGATTATTTTTTGGTT-3′ (reverse); CYP1A1-14a, 5′-CTAATCCAAACCAAAAAATAATCCC-3′ (forward); CYP1A1-14b, 5′-AAATAATCCCCTCACCTCCCATTCC-3′ (forward); CYP1A1-15, 5′-TGTTTTTTTTTATTAGAATGTAAAT-3′ (reverse); CYP1A1-15b, 5′-GAGATTAGGAGTGTTGTTAGTTGTG-3′ (reverse); CYP1A1-16, 5′-TAGATTTGGGGTATATTATTTGTTT-3′ (reverse); and CYP1A1-17, 5′-TTGATTTTTTTGTTTTGAATTGTAA-3′ (reverse).
4/16 cancerres.aacrjournals.org/content/66/15/7420.full PCR conditions were as follows: 3 minutes at 94°C, 35 cycles of 1 minute at 94°C, 30 seconds at 56°C, and 1 minute at 72°C followed by 5 minutes at 72°C extension step. Second-round PCR was done using 1 μL of the first-round PCR product in a total volume of 50 μL. The amplification product was confirmed by electrophoresis on a 2% agarose gel and sequenced directly by an outside vendor (McLab, South San Francisco, CA).
Quantitation of CpG methylation. The methylation level of individual
CpG sites on CYP1A1 was estimated directly by comparing the height of the cytosine peak with the height of the thymine peak on the DNA sequencing chromatogram. A single cytosine peak was considered to represent 100% methylation; a single thymine peak was considered to represent no methylation. CpG sites with overlapping cytosine and thymine peaks were considered to be partially methylated. In the latter instance, the percentage of methylation was calculated as the ratio of the peak heights of the cytosine to cytosine plus thymine signals.
The methylation level of CYP1A1 CpG sites 52 to 85 was also estimated by sequencing individual DNA strands. Bisulfite-modified DNA was amplified using primers CYP1A1-7 (forward) and CYP1A1-10 (reverse) in the primary reaction and primers CYP1A1-8 (forward) and CYP1A1-10 (reverse) in the secondary reaction. The PCR product was cloned into pSC-A using the StrataClone PCR Cloning kit according to the manufacturer's directions (Stratagene, La Jolla, CA). Individual clones were picked and grown, and plasmid DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen) and sequenced by an outside vendor (McLab) using the T3 primer.
In vivo footprinting. In vivo footprinting using dimethyl sulfate (DMS; Sigma) was done as described previously ( 13, 14 ethidium bromide. The sequence of the primers used in the ChIP analysis were as follows: promoter, 5′-CCGCCACCTTTCTCTCCAATCCCAG-3′ (forward) and 5′-ATAGGCGGGCTTGTACGTGTGGCCA-3′ (reverse); DRE 3, 5′-TCAGGGCTGGGGTCGCAGCGCTTCT-3′ (forward) and 5′-GCTACAGCCTACCAGGACTCGGCAG-3′ (reverse); DRE 4, 5′-
TGACCTCTGCCCCCTAGAGGGATGT-3′
(forward) and 5′-TTGGCAGAGCACAGAAATCCGGCGG-3′ (reverse); DRE 5 to 6, 5′-
TTTAAGAGCCCCGCCCCGACTCCCT-3′
(forward) and 5′-CAGGCGTTGCGTGAGAAGGACCGGA-3′ (reverse); DRE 10, 5′-
GTCGGGGATGGCGCGTAACGATGTT-3′
(forward) and 5′-CCTCCGGAACCTTCCTGTTACAGGG-3′ (reverse); upstream, 5′-AAGGCCTTCCCTGACCCCCTTGTTT-3′
(forward) and 5′-GCTGACAGCACTCCTAATCTCGTGG-3′ (reverse); and G3PDH, 5′-TACTAGCGGTTTTACGGGCGCACGT-3′ (forward) and 5′-TCGAACAGGAGGAGCAGAGAGCGAA-3′ (reverse).
Results
Effect of 5-aza-CdR on CYP1A1 expression. 5-Aza-CdR, a nucleotide analogue that demethylates genomic DNA, is commonly used to determine if DNA methylation influences gene expression ( 15, 16) . We treated two noncancerous human prostate cell lines (PWR-1E and RWPE-1) and one cancerous human prostate cell line (LNCaP) with 5-aza-CdR to assess its effect on constitutive and TCDD-inducible CYP1A1 mRNA expression. Our results ( Fig. 1 ) reveal striking differences between the cancerous and noncancerous cell lines. Both of the noncancerous cell lines exhibit low basal CYP1A1 expression that is dramatically increased following TCDD exposure. 5-Aza-CdR has little effect on constitutive or TCDD-induced CYP1A1 expression. This pattern of CYP1A1 expression is consistent with its expression in most healthy animal tissues and, thus, is considered normal. In contrast, in the cancerous LNCaP cells, basal CYP1A1 expression is not detectable and is only barely detectable in cells exposed to TCDD. 5-Aza-CdR dramatically increases the TCDD inducibility of CYP1A1 in a dosedependent fashion; no effect on constitutive CYP1A1 expression is observed ( Fig. 1 ). This pattern of CYP1A1 expression is aberrant and suggests that cancer-associated DNA methylation suppresses TCDD induction of CYP1A1. ( Fig. 1) . We find that AhR is expressed at a lower level and Arnt is expressed at a slightly higher level in LNCaP cells relative to the noncancerous cell lines. 5-Aza-CdR has little effect on AhR or Arnt expression in all cells. We conclude that DNA methylation does not significantly influence AhR or Arnt expression in LNCaP cells. We therefore infer that direct methylation of CYP1A1 likely suppresses its TCDD inducibility.
CpG islands on the CYP1A1 enhancer. In human cancers, CpG sites are often hypermethylated, resulting in aberrant suppression of gene expression ( 1, 2) . CpG sites that affect gene expression are typically located in CpG islands in gene regulatory regions. To identify CpG islands on the CYP1A1 gene locus (defined as 50 kb upstream and 25 kb downstream of the CYP1A1 transcriptional start site), we analyzed it using "the CpG island searcher" developed by Takai and Jones ( 17) . We find that only two CpG islands exist within this 75-kb region ( Fig. 2A ) .
One of the CpG islands (CpG island 2) is located between −2,813 and −3,567 bp upstream of the CYP1A1 transcription start site; the function of this region is unknown. The other CpG island (CpG island 1) occurs between −178 and −1,712 bp upstream of the CYP1A1 transcription start site. This region, previously identified as the CYP1A1 enhancer, confers dioxin inducibility and contains all of the DRE sites that are implicated in dioxin induction of CYP1A1 ( Fig. 2B; refs. 7, 18) . Thus, the dioxinresponsive CYP1A1 enhancer is contained within a CpG island, a DNA region susceptible to DNA methylation. ( Fig. 2B; refs. 7, 18 ). In RWPE-1 cells ( Fig. 3B ) , we do not detect methylation of CpG sites 1 to 90. Thus, in these noncancerous prostate cells, the entire CYP1A1 regulatory region is unmethylated and is not constrained in its ability to control transcription. We detect methylation of CpG sites 91 to 125. However, this methylated DNA is upstream of the CYP1A1 regulatory region and is not known to control gene expression. In LNCaP cells, we detect methylation of CpG sites 37 to 90 ( Fig. 3B) . These sites are not methylated in RWPE-1 cells and encompass the TCDD-responsive CYP1A1 enhancer. We also find that the CYP1A1 promoter is not methylated (CpG sites 1-36) and DNA upstream of the regulatory region of CYP1A1 is highly methylated (CpG sites 91-125) in LNCaP cells. This pattern of DNA methylation is similar to that observed in RWPE-1 cells and suggests that these regions are not associated with the differential 5-aza-CdR sensitivity observed in our gene expression experiment ( Fig. 1) . Together, these results imply that cancer-dependent enhancer hypermethylation suppresses TCDD induction of CYP1A1. We also determined the methylation pattern on the CYP1A1 enhancer in individual DNA strands by cloning the bisulfite PCR product into a plasmid vector and sequencing individual clones. As expected, no DNA
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Epigenetic Inactivation of the Dioxin-Responsive Cytochrome P4501A1 Gene in Human Prostate C… 8/16 cancerres.aacrjournals.org/content/66/15/7420.full methylation was detected in 10 clones derived from RWPE-1 DNA and in 12 clones derived from PWR-1E DNA (data not shown). In contrast, all 20 clones derived from control LNCaP DNA exhibited a unique pattern of DNA methylation ( Fig. 3C) . Of the 34 CpG sites analyzed, the number of methylated sites ranged from 12 to 28 with an average of 18.4.
Importantly, the percentage of methylation of each individual CpG site determined in this analysis was similar to that determined by direct sequencing of the PCR products ( Fig. 3C) . This serves to validate our method used to quantitate DNA methylation and clearly shows that, within the CYP1A1 enhancer, individual CpG sites exhibit widely different levels of DNA methylation.
We also assessed CYP1A1 enhancer methylation in LNCaP cells treated with 5-aza-CdR for 7 or 14 days. We find that cells treated for 7 days had ∼15% less methylation than control cells (data not shown). Remarkably, in LNCaP cells treated with 5-aza-CdR for 14 days, the CYP1A1 enhancer is almost entirely devoid of methylation. Of the 20 clones analyzed, 17 had no detectable DNA methylation and the other 3 clones were methylated at only a single CpG site ( Fig. 3C) . We conclude that the CYP1A1 enhancer is sensitive to demethylation by 5-aza-CdR. ( Fig. 3D) . To assess the functionality of these sites, we analyzed them by in vivo footprinting ( Fig. 4 ) . First, within the CYP1A1 enhancer, we analyzed DREs 3 and 6, sites that are unmethylated in both LNCaP and RWPE-1 cells. As a positive control, we analyzed DRE occupancy in dioxin-responsive RWPE-1 cells. We find that TCDD induces dramatic changes in the DMS modification pattern of bases within the DREs. One base exhibits TCDD-inducible DMS hypersensitivity, and two other bases exhibit TCDD-dependent DMS hyposensitivity ( Fig. 4A and B) . This pattern of DMS modification reflects TCDD-inducible DRE occupancy ( 18) and implies that, in RWPE-1 cells, DREs 3 and 6 are functionally active and are occupied by AhRC in response to TCDD. In contrast, in LNCaP cells treated with TCDD, we do not detect any changes in the DMS modification pattern and therefore infer that DREs 3 and 6 remain unoccupied. In LNCaP cells cotreated with 5-aza-CdR and TCDD, we observe a slight change in the DMS modification pattern consistent with partial DRE occupancy ( Fig. 4A and   B ). This partial DRE occupancy is consistent with the partial restoration of CYP1A1 mRNA inducibility observed in LNCaP cells cotreated with TCDD and 5-aza-CdR ( Fig. 1) . Together, these findings show that DREs 3 and 6, although unmethylated, are functionally inactive in LNCaP cells and that inhibition of DNA methylation partially restores their activity. Because DNA methylation cannot directly block AhRC binding at these sites, we conclude that it acts indirectly to inhibit AhRC access. In vivo footprinting of AhRC-binding sites. Cells treated with 5-aza-CdR (1 μmol/L) for 7 days and/or TCDD (10 nmol/L) for 2 hours were analyzed by in vivo footprinting as described previously ( 13, 14) . N, naked genomic DNA treated with DMS in vitro was also analyzed. We next analyzed DRE 10, a site upstream of the CYP1A1 enhancer that is highly methylated in both LNCaP and RWPE-1 cells ( Fig. 3D) . Here, we do not observe any TCDD-inducible change in the DMS modification pattern in either cell type ( Fig. 4C ). This observation is consistent with the findings of Kress et al. ( 18) . We conclude that DRE 10 does not bind protein in vivo and is therefore nonfunctional.
We also analyzed DREs 4 and 5, sites that are highly methylated in LNCaP cells but not in RWPE-1 cells ( Fig. 3D) . In RWPE-1 cells, we observe a TCDD-dependent change in the DMS modification pattern consistent with AhRC binding (data not shown). Therefore, DREs 4 and 5 are functional in noncancerous human prostate cells. However, in LNCaP cells, we cannot detect a TCDD-dependent change in the DMS modification pattern even after the cells have been cotreated with 5-azaCdR for 7 days (data not shown). We observe that this level of 5-aza-CdR treatment decreases DNA methylation at these sites by ∼15% (data not shown). Therefore, at these sites, DNA methylation likely exerts both a direct effect that prevents AhRC binding in addition to its indirect effect noted above.
Effect of TCDD and DNA methylation on chromatin structure. We suspected that the indirect effect associated with DNA methylation that prevents AhRC binding might be related to the local chromatin structure.
Some chromatin configurations, such as histone hyperacetylation and methylation of lysine 4 on histone H3 (H3K4), are associated with transcriptionally active genes and an accessible chromatin structure.
Other chromatin configurations, such as histone hypoacetylation and methylation of lysine 9 of histone H3 (H3K9), are associated with silenced genes and a relatively inaccessible chromatin structure (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Using ChIP methodology, we analyzed the chromatin structure of key regulatory regions within CpG island 1 and flanking DNA sequences (  Fig. 5 ) . In dioxin-responsive PWR-1E and RWPE-1 cells, TCDD treatment increases the acetylation of histones H3 and H4 on the CYP1A1 promoter ( Fig. 5B ). This finding is consistent with previous reports ( 29, 30) and is likely due to AhRC's recruitment of proteins with histone acetyltransferase (HAT) activity ( 31) . We also detect TCDD increased histone acetylation in the heavily methylated DNA region upstream of the regulatory elements of CYP1A1 ( Fig. 5B, DRE 10 and upstream) . This finding shows that the HAT activity recruited by AhRC does not target the CYP1A1 promoter with specificity and that it can modify histones associated with methylated DNA. We do not observe a TCDD-dependent change in histone acetylation in LNCaP cells; this finding is expected due to the inability of AhRC to bind to the CYP1A1 enhancer ( Fig. 4) .
Importantly, we do not detect any cell line-specific differences in the basal level of histone acetylation in the vicinity of DRE 3. Therefore, histone H3 and H4 acetylation is not associated with the inability of AhRC to bind to DRE 3 in LNCaP cells.
In contrast to our results assessing histone acetylation, we do not detect a TCDD-inducible increase in the level of H3K4 methylation (both dimethylated and trimethylated forms) on CYP1A1 ( Fig. 5B ). We note a slight but significant TCDD-dependent decrease in H3K4 methylation in the vicinity of some DREs in the dioxin-responsive cell lines. This finding is consistent with that of Kim et al. ( 32) , who report that H3K4 methylation is decreased on an activated enhancer. In LNCaP cells, there is less H3K4 methylation in the cancer-specific DNA methylation region than in the noncancerous cell lines ( Fig. 5B, DRE 4 and DRE [5] [6] . We also observe less H3K4 methylation in the methylated region of the CYP1A1 gene relative to the nonmethylated region in the noncancerous cell lines (compare the band intensity of dimethylated and trimethylated H3K4 relative with the input control in the upstream and the promoter panels).
Together, these data indicate that H3K4 methylation is decreased in regions containing methylated DNA.
Surprisingly, we find striking differences in the levels of dimethyl H3K4 and trimethyl H3K4 within the CYP1A1 regulatory region ( Fig. 5B) .
Dimethyl H3K4 is prevalent and present at approximately equal levels on the CYP1A1 promoter and DRE 3 region in all cell types. In contrast, trimethyl H3K4 is found at much lower levels in these regions in LNCaP cells relative to PWR-1E and RWPE-1 cells. These data show that, on and heavy (>50%). We could not detect CYP1A1 enhancer methylation in any of the DNA samples isolated from noncancerous prostate tissue (data not shown). In contrast, we detect CYP1A1 enhancer methylation in 36% (11 of 30) of the DNA samples isolated from prostate tumors ( Fig. 6 ). This finding shows that the CYP1A1 enhancer is aberrantly hypermethylated in human prostate cancer. Within the 11 positive DNA samples, the pattern and extent of CYP1A1 enhancer methylation varies considerably ( 
Discussion
Dioxin is a notorious environmental contaminant that is highly toxic to experimental animals and is classified as a group 1 human carcinogen by the IARC. This classification, however, is controversial, and the risk that dioxin poses to human health is uncertain ( 4-6). Clearly, continued work analyzing dioxin action in humans is necessary to resolve this important issue.
12/16 cancerres.aacrjournals.org/content/66/15/7420.full Transcriptional induction of CYP1A1 is a widely used model system to study mechanistic aspects of dioxin action ( 7) . In this study, we analyze the effects of DNA methylation on CYP1A1 induction and dioxin action in cultured human prostate cells and in human prostate tissue samples. The prostate gland is highly sensitive to dioxin. Studies in rats show that dioxin induces CYP1A1 in prostate tissue and elicits adverse developmental effects (33) (34) (35) (36) . In humans, there is limited/suggestive evidence of an association between dioxin exposure and prostate cancer ( 37). We find that, in LNCaP cells, a cancerous prostate cell line, dioxin induction of CYP1A1 is severely repressed by DNA methylation. In addition, in human prostate tumors, the CYP1A1 enhancer is aberrantly hypermethylated. Importantly, some prostate tumors exhibit a pattern of DNA methylation similar to that observed in LNCaP cells ( Fig. 6) . These tumors are likely impaired in their ability to induce CYP1A1 in response to dioxin.
In our study, we determine the methylation status of all CpG sites within and flanking a CpG island that encompasses the CYP1A1 regulatory region. Interestingly, we find that within the CpG island DNA methylation is not uniform and falls into distinct domains that closely align with Trimethyl H3K4 is exclusively associated with active genes ( 22, 23) . Our ChIP experiments show that, in LNCaP cells, trimethyl H3K4 is dramatically depleted in the DNA regions containing DREs 3 and 6. This altered chromatin structure is likely associated with the inability of AhRC to interact with these sites and, thus, possibly represents the indirect effect associated with DNA methylation that renders the DNA nonfunctional. Recent reports show that specific proteins catalyze H3K4 trimethylation and that histone demethylation is dynamically regulated ( 38-43). We envision that DNA methylation depletes trimethyl H3K4 to generate a repressive, inaccessible chromatin structure. Depletion of H3K4 might be accomplished by inhibiting H3K4 trimethylation or by inducing a demethylase specific for trimethyl H3K4. Future studies that explore the relationship between DNA methylation, chromatin structure, and DNA accessibility will provide insights into these intriguing possibilities.
13/16 cancerres.aacrjournals.org/content/66/15/7420.full Our finding that CYP1A1 is aberrantly hypermethylated in prostate cancer is novel. This finding adds CYP1A1 to an expanding list of genes that display hypermethylation in prostate tumors ( 44, 45) . It is unclear if CYP1A1 hypermethylation is restricted to prostate cancer or if the gene is hypermethylated in cancers at other sites. A study analyzing human lung tissue indicates that CYP1A1 methylation is not altered in lung cancer ( 11) . In cell line studies, the CYP1A1 enhancer exhibits partial methylation in human MCF-7 and HeLa cells ( 12) . In addition, cultured rabbit kidney and lung cells display partial CYP1A1 enhancer methylation ( 10) . Future work analyzing CYP1A1 methylation in other organs may provide insight into tissue-specific and cancer-related regulation of CYP1A1 gene expression.
CYP1A1 encodes a cytochrome P450 that metabolizes polycyclic aromatic hydrocarbons and contributes to both their detoxification and, paradoxically, their bioactivation into toxic and mutagenic intermediates ( 5). It is currently unclear if CYP1A1 induction has a positive or negative effect toward animal health ( 46) . Therefore, the medical significance of our finding that CYP1A1 induction is compromised in some prostate tumors is unclear.
